GIE Groupe hospitalier Paris Saint-Joseph

At GIE Groupe hospitalier Paris Saint-Joseph, the diabetology, endocrinology, and nutrition team is conducting studies in hormonal diseases and pathological conditions, with a strong focus on type 2 diabetes. This research is aimed at improving glucose control and evaluating whether newer treatment strategies can offer better long-term outcomes for people living with diabetes.

• Type 2 diabetes and treatment switching
• Hormonal disease management
• Improving blood sugar control and treatment effectiveness

The site’s work in this area reflects a practical effort to refine everyday care for patients with chronic metabolic disease.

A major part of the trial portfolio covers neoplasms, including biliary tract carcinoma, hepatocellular carcinoma, advanced solid tumors, and colorectal cancer. These studies are designed to test new treatment combinations, improve survival, and support more effective cancer control in difficult-to-treat disease settings.

• Biliary tract carcinoma and adjuvant treatment
• Hepatocellular carcinoma and first-line therapy
• Advanced solid tumors and anti-cancer combinations

This oncology research also includes studies in lung cancer, rectal adenocarcinoma, and metastatic colorectal cancer, showing a broad interest in both localized and advanced cancer care.

The site is active in respiratory tract diseases, especially advanced non-small cell lung cancer, maintenance treatment in metastatic lung cancer, and interstitial lung disease. These trials are focused on improving disease control, extending survival, and better managing progressive lung conditions.

• Non-small cell lung cancer treatment strategies
• Interstitial lung disease and lung function
• Evaluating new cancer therapies and supportive treatment approaches

Research in this area combines cancer care and chronic lung disease management, highlighting the site’s interest in both therapeutic innovation and patient outcomes.

Clinical trials in cardiovascular diseases at this hospital include studies on acute ischemic stroke, high-risk transient ischemic attack, and atherosclerotic cardiovascular disease. The main purpose is to assess whether new approaches can reduce the risk of serious vascular events and improve protection for high-risk patients.

• Stroke prevention after acute cerebrovascular events
• Atherosclerotic cardiovascular disease in complex patients
• Testing new preventive treatments for vascular risk reduction

This work supports better long-term management of patients at risk of recurrent ischemic events.

The research portfolio also includes bacterial infections and skin and connective tissue diseases, with studies in hospital-acquired bacterial pneumonia and hidradenitis suppurativa. These trials are exploring improved antibiotic strategies and better symptom control for persistent inflammatory skin disease.

• Hospital-acquired bacterial pneumonia treatment
• Hidradenitis suppurativa symptom reduction
• Evaluating new anti-infective and anti-inflammatory options

The goal is to improve recovery from serious infections while also addressing chronic, painful skin conditions that can strongly affect quality of life.

Trials in digestive system diseases and female urogenital diseases and pregnancy complications include research on endometriosis-related pain, preeclampsia, and rectal adenocarcinoma. These studies aim to improve symptom relief, protect maternal health, and support better outcomes in gastrointestinal and pelvic disease.

• Endometriosis pain management
• Preeclampsia prevention in pregnancy
• Rectal cancer organ-preserving treatment

This area shows a strong interest in both women’s health and digestive oncology, with an emphasis on treatment benefit and patient-centered care.

The site is also involved in studies linked to immune system processes and analytical, diagnostic, and therapeutic techniques. These trials include research in progressive interstitial lung disease and other advanced conditions, with the aim of evaluating whether targeted therapies can improve function, control disease activity, and offer better clinical benefit.

• Immune-related treatment approaches
• Progressive interstitial lung disease with inflammatory features
• Assessing new therapeutic options for difficult-to-treat disease

This research reflects a broader commitment to innovative care across complex chronic and advanced illnesses.